Business · 15/02/2018Updated: 10/17/2026 · 1 min read
FDA Sets Regulatory Review Period for ZYDELIG New Drug Application
Summary
The US Food and Drug Administration (FDA) has officially determined the review period for ZYDELIG, a new drug application (NDA 205858), following a request from the US Patent and Trademark Office (USPTO) to extend a patent related to the human drug product and NDA.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →